rls

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Cyclo(RLsKDK) (BK-1361) serves as a targeted inhibitor of the metalloproteinase ADAM8, demonstrating efficacy with an IC50 value of 182 nM. This compound shows promise for use in the treatment of inflammatory diseases and cancer, highlighting its potential therapeutic applications.

Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Pegtarazimod (RLS-0071) inhibits the complement system through both the classical and lectin pathways. It suppresses myeloperoxidase (MPO) activity, leading to reduced ROS production, and decreases the formation of neutrophil extracellular traps (NET). Pegtarazimod exhibits anti-inflammatory properties and is applicable in the study of acute graft-versus-host disease.